Wireframe Ventures’ Post

TerrayTherapeuticsAdvances #AIInPharma Terray Therapeutics has secured $120 million in funding to boost its AI-driven small-molecule drug development platform. Led by Bedford Ridge Capital and NVentures, this investment supports Terray's mission to revolutionize drug discovery using its AI model, tNova. The company boasts a vast chemistry dataset, significantly enhancing drug development success rates. Partnerships with Bristol Myers Squibb and Calico Life Sciences highlight Terray's industry influence. #TerrayTherapeutics #AIDrugDevelopment #Biotech #PharmaInnovation #Saasverse What role do you think AI will play in the future of drug development?

//WEBINAR// Tune in on March 7 at 2:00 PM EST to discover which strategies and resources can optimize your path to clinic. Join our scientific experts, Sam Chuang and Manu Kohli, as they discuss which strategies and resources can best help you minimize expensive preclinical roadblocks and obtain guidance on target to in vivo #pharmacology workflows. https://okt.to/BwyNqx #invivo #biotech #drugdiscovery #preclinicial #startup

//WEBINAR// Tune in on March 7 at 2:00 PM EST to discover which strategies and resources can optimize your path to clinic. Join our scientific experts, Sam Chuang and Manu Kohli, as they discuss which strategies and resources can best help you minimize expensive preclinical roadblocks and obtain guidance on target to in vivo #pharmacology workflows. https://okt.to/7FsKm6 #invivo #biotech #drugdiscovery #preclinicial #startup

//WEBINAR// Tune in on March 7 at 2:00 PM EST to discover which strategies and resources can optimize your path to clinic. Join our scientific experts, Sam Chuang and Manu Kohli, as they discuss which strategies and resources can best help you minimize expensive preclinical roadblocks and obtain guidance on target to in vivo #pharmacology workflows. https://okt.to/BxpS0C #invivo #biotech #drugdiscovery #preclinicial #startup

//WEBINAR// Tune in on March 7 at 2:00 PM EST to discover which strategies and resources can optimize your path to clinic. Join our scientific experts, Sam Chuang and Manu Kohli, as they discuss which strategies and resources can best help you minimize expensive preclinical roadblocks and obtain guidance on target to in vivo #pharmacology workflows. https://okt.to/o4RiUI #invivo #biotech #drugdiscovery #preclinicial #startup

👏💰Congratulations to CN Bio for their $21million USD Series B investment round! Investment of $10M from Bayland Capital 康君资本 and $5.5M from founding shareholder, CN Innovations Holdings Ltd will be used to expand product development, to meet increased demand for Organ-on-a-Chip (OOC) solutions. With 80% of clinical failures attributed to efficacy and toxicity issues, often derived from the poor predictiveness of animal and 2D cell culture models, the demand for OOC solutions in these areas is growing. 
This expansion will enhance the depth and breadth of tools and applications available to optimise drug discovery and development workflows, enabling researchers to generate data with greater predictability, lower risks of late-stage failures, and accelerate time-to-market for a wide-range of novel therapeutics. #lifesciences #funding #investment https://lnkd.in/dpW-qYrj Paul Brooks Yuexing Su

🎉 We are thrilled to announce that we've hit 1,000 followers on LinkedIn!   A heartfelt thank you to each of you for your incredible support, engagement, and valuable connections.    This milestone does not only reflect our growth here at LinkedIn, but also as a company. Since #Secarna Pharmaceuticals’ founding in 2015, our focus has been on antisense therapeutics, and with increasing focus on targeted antisense oligonucleotides (ASOs) developed through our advanced AI-powered #ASO platform. Our work and that of others active in the field has established ASOs as a vital class of therapeutic molecules.   What’s next? We currently see a rapidly growing number of development candidates: According to a July 2024 GlobalData Plc search, there are more than 100 ASO candidates in Phase 2 or 3 clinical development and we anticipate a significant increase in ASO #therapies launching in the coming years. With this momentum, Secarna is aiming for an exciting future, aiming to translate our preclinical findings into clinical data and developing new and effective targeted treatments - for the benefit of patients around the world. Here's to more learning, networking, and growth! 🙌 #Biotech #Innovation #LifeSciences

Zhinan Xia, CEO & Founder of @Abimmune Bio, presenting at Day 2 of the 7th Alcor Drug Discovery Platform! Join us as Zhinan introduces their cutting-edge Novel ADC platform, paving the way for transformative therapies. Don't miss out on this opportunity to explore the future of targeted drug delivery! #AlcorDrugDiscovery #ADCPlatform #Innovation #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits

Make sure to tune in next week to learn more about how you can streamline your path to clinic!